EAI045

Min.Order / FOB Price:Get Latest Price

0	Negotiable

Min.Order :0
Purity: 95%

Keywords

2-(5-fluoro-2-hydroxyphenyl)-2-(3-oxo-1H-isoindol-2-yl)-N-(1,3-thiazol-2-yl)acetamide 2-(5-fluoro-2-hydroxyphenyl)-2-(1-oxo-2,3-dihydro-1H-isoindol-2-yl)-N-(1,3-thiazol-2-yl)acetamide

Quick Details

Appearance:Solid powder
Application:For research use only.
PackAge:50 mg
ProductionCapacity:
Storage:Store in a cool and dry place and at 0 - 4°C for short term (days to weeks) or -42°C for long term (months to years).
Transportation:

Superiority:

We provide customized and high-quality EAI045 product for your project.

Details:

EAI045 is an allosteric, non-ATP competitive inhibitor of mutant EGFR. In vitro studies proved that EAI045 is active and selective for T790M- harboring EGFR mutants that are in a monomer state. In vivo the combination of EAI045 and cetuximab caused a marked tumor shrinkage in a mouse model carrying the EGFR mutant with L858R/T790M/C797S. Therefore, EAI045 is the first allosteric inhibitor that targets T790M and C797S EGFR mutants but it is effective only in combination with cetuximab.

View All